Photo from wikipedia
This pooled analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) and Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure… Click to show full abstract
This pooled analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) and Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure (DELIVER) trials investigates the effect of dapagliflozin on specific causes of cardiovascular mortality across the spectrum of ejection fraction.
Keywords:
ejection fraction;
heart failure;
dapagliflozin
Journal Title: JAMA Cardiology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: JAMA Cardiology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!